Pasithea Therapeutics Stock (NASDAQ: KTTA)

Pasithea Therapeutics Stock (NASDAQ:KTTA), Trade Ideas

Pasithea Therapeutics

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia.

Earnings

News

Penny Stocks

Eurozone

Commodities

Small Cap

Global

Intraday Update

Markets

Trading Ideas

COGT

KTTA

Morgan Stanley Capital Protected Notes for S&P 500 Index

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 100 points on Monday.

The Dow traded up 0.26% to 36,341.44 while the NASDAQ rose 0.12% to 14,421.98. The S&amp;P 500 also rose, gaining, 0.30% to 4,618.11.

Nasdaq Edges Higher; Macy&#39;s Shares Jump

Movers

AAGR

APLS

BLUE

BMEA

BPMC

BTBT

CLSK

COMM

CYTO

DISH

DOGZ

EFTR

HIVE

IONM

IPDN

ISUN

JTAI

KROS

MARA

MINM

NXTP

ONTX

RIOT

SHAK

TRKA

VAPO

VERU

WULF

XFOR

ZLAB

Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting &amp; Exposition.

Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining more than 100 points on Monday.

The Dow traded up 0.28% to 36,349.22 while the NASDAQ fell 0.36% to 14,352.34. The S&amp;P 500 also rose, gaining, 0.06% to 4,607.02.

Dow Surges 100 Points; Cogent Biosciences Shares Plunge

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics Corp

Guidance

UBSI

United Bankshares Sees FY24 Outlook; Sees Net Interest Income To Be In The Range Of $900M-$915M For 2024. Expect The Net Interest To Remain Stable In 2024 Compared To Q1

Integer Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITGR#NYSE">ITGR</a>) reported quarterly earnings of $1.14 per share which beat the analyst consensus estimate of $1.11 by 2.7 percent. This is a 31.03 percent increase over earnings of $0.87 per share from the same period last year. The company reported quarterly sales of $414.805 million which beat the analyst consensus estimate of $412.825 million by 0.48 percent. This is a 9.51 percent increase over sales of $378.785 million the same period last year.

Earnings Beats

ITGR

Integer Holdings Q1 2024 Adj EPS $1.14 Beats $1.11 Estimate, Sales $414.805M Beat $412.825M Estimate

Tech

IBM Unveils New Storage Capabilities Through IBM Storage Assurance

Oppenheimer analyst Michael Wiederhorn maintains Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Outperform and lowers the price target from $415 to $370.

Price Target

Analyst Ratings

Oppenheimer Maintains Outperform on Humana, Lowers Price Target to $370

DA Davidson analyst Linda Bolton Weiser maintains Helen Of Troy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HELE#NASDAQ">HELE</a>) with a Buy and lowers the price target from $151 to $139.

HELE

DA Davidson Maintains Buy on Helen Of Troy, Lowers Price Target to $139

United Bankshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBSI#NASDAQ">UBSI</a>) reported quarterly earnings of $0.64 per share which missed the analyst consensus estimate of $0.65 by 1.54 percent. This is a 12.33 percent decrease over earnings of $0.73 per share from the same period last year.

United Bankshares Q1 EPS $0.64 Misses $0.65 Estimate

On Nov. 19, Anthony Scaramucci, founder and managing partner of SkyBridge Capital, will speak at Benzinga's Future of Digital Assets conference. 
The event, which will be held at Convene 225 Liberty Street in New York City, aims to connect and educate leaders from digital and traditional finance.
<h3 class="wp-block-heading">Extensive Financial Expertise</h3>
Anthony Scaramucci has built a notable career in the financial world. 
He began at Goldman Sachs, where he honed his skills across several departments, including investment banking and private wealth management. 
After leaving Goldman Sachs, he co-founded Oscar Capital Management, which successfully sold to Neuberger Berman in 2001.
In 2005, he established SkyBridge Capital, which has grown into a global leader in alternative investments.
<h3 class="wp-block-heading">Political And Strategic Roles</h3>
Beyond his financial career, Scaramucci has also been active in political and strategic roles. He served on President Donald J. Trump's 16-person Presidential Transition Team Executive Committee. 
In 2017, he briefly held positions as chief strategy officer of the Export-Import (EXIM) Bank and White House communications director. 
These experiences have given him a unique political, finance, and strategy background.
<h3 class="wp-block-heading">Acknowledged Leader In Finance</h3>
Scaramucci's contributions to the financial industry have been recognized with several awards and rankings. Notably, he was featured in Cointelegraph's Top 100 Influencers in Crypto and Blockchain in 2022. 
He received Ernst &amp; Young's New York Financial Services Entrepreneur of the Year Award in 2011. His influence extends beyond business as he serves on the Council on Foreign Relations and the Federal Enforcement Homeland Security Foundation board.
<h3 class="wp-block-heading">Why Should You Attend?</h3>
At the Benzinga conference, Scaramucci is expected to deliver valuable insights into merging digital and traditional financial landscapes. 
His discussion will likely focus on how financial institutions can effectively incorporate digital assets into their investment strategies. 
Given his extensive background in creating and managing investment opportunities in a changing economic environment, attendees can look forward to strategic advice from Scaramucci.
Image: Anthony Scaramucci. Photo by World Economic Forum on Flickr

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Financing

Events

Join Anthony Scaramucci In NYC For The Future Of Finance's Digital Era

TriCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBK#NASDAQ">TCBK</a>) reported quarterly earnings of $0.83 per share which beat the analyst consensus estimate of $0.80 by 3.75 percent. This is a 22.43 percent decrease over earnings of $1.07 per share from the same period last year. The company reported quarterly sales of $98.507 million which missed the analyst consensus estimate of $100.039 million by 1.53 percent. This is a 7.91 percent decrease over sales of $106.971 million the same period last year.

Earnings Misses

TCBK

TriCo Q1 2024 GAAP EPS $0.83 Beats $0.80 Estimate, Sales $98.507M Miss $100.039M Estimate

Oppenheimer analyst Michael Wiederhorn maintains Community Health Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYH#NYSE">CYH</a>) with a Outperform and lowers the price target from $5.5 to $4.5.

Oppenheimer Maintains Outperform on Community Health Sys, Lowers Price Target to $4.5

Worksport Signals Undervalued Status, Eyes Major 2024 Growth
West Seneca, New York 04-25-2024 - Worksport Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKSP#NASDAQ">WKSP</a>, WKSPW)))), a U.S.-based manufacturer dedicated to developing innovative hybrid and clean energy solutions in light truck, overlanding, and global consumer goods markets, today released a memo to shareholders, iterating management's outlook on maximizing shareholder value and setting the stage for a transformative year in projected growth for 2024, on all fronts.&nbsp;
"As we steer through a pivotal phase at Worksport, our direction is clear and aimed at reinforcing our position as a leader in truck accessories and sustainable automotive solutions," said Steven Rossi, CEO &amp; President of Worksport. "With our focus on delivering innovative products that cater to the booming pickup truck, overlanding, and off-roading communities, we have just begun capturing our share of these significant market segments."
Corporate Valuation and Growth Outlook:
●&nbsp;Undervalued Stock Potential: With over 150 registered and pending patents and trademarks, a state-of-the-art facility valued at over $9.2 million-exceeding our current market cap-and advanced manufacturing equipment valued at more than $7 million, it is our belief that Worksport stock is significantly undervalued.
●&nbsp;Year-end sales for 2024 are expected to significantly increase from the previous year, primarily driven by Worksport's U.S.-made hard covers along with highly anticipated green-energy products coming this summer. Having already generated significant press and industry interest, the market introduction of the SOLIS solar cover and the COR portable energy storage system in the months ahead is expected to exponentially boost growth potential and substantially enhance shareholder returns.
Strategic Inventory and Production Milestones:
●&nbsp;Robust Inventory and Supply Chain Stability: With a robust balance of inventory to produce new products, a significant revenue growth opportunity is present, and is being met by strong demand for the Company's Made in America hard-covers. The Company is confident in its ability to produce significant volumes and capitalize on increasing demand without delay.
●&nbsp;B2C Sales Momentum: Direct-to-consumer sales campaigns initiated in March 2024 have already led to an uptick in sales, with sales figures from April 2024 already surpassing internal projections, indicating robust consumer demand and market acceptance.
●&nbsp;Accelerated B2B Engagements: An overwhelmingly positive reception from major U.S. business customers, including initial purchase orders from three leading players, has accelerated the Company's B2B pipeline, while marking a significant vote of confidence in Worksport's technology and business model.
Innovation and Market Expansion:
●&nbsp;First-to-Market Solar Truck Bed Cover: Finalized after extensive engineering and prototyping, the patented SOLIS cover is set for its market debut this summer. As a pioneer in the solar technology space, capturing even 5% of the U.S. market translates to significant revenue potential, potentially exceeding $300 million annually from the solar cover line alone. The SOLIS Solar Truck Bed Cover will be among the very first to market and will be available for all major makes and models. The Company has received copious interest from the media, industry partners, and consumers for this forthcoming innovation.
●&nbsp;COR Solid State Power Generator Launch: Complementing the SOLIS cover, the patent pending COR battery system is nearing the end of its prototyping phase. With each SOLIS unit sold, a COR unit stands as its perfect counterpart, enhancing utility and customer value. Alpha units of the COR system are expected to be available by this summer with strong interest from US Government Agencies &amp; Major Retailers.
●&nbsp;Groundbreaking Heat Pump Technology: Additionally, Worksport subsidiary, Terravis Energy, Inc., is on the brink of completing an innovative residential heat pump that surpasses existing technological standards by up to 40%. With the global heat pump market projected to grow at a CAGR of 8.5%, reaching $142.4 Billion by 2030, this development has garnered significant interest from conglomerate companies and governments worldwide.
Grants and Intellectual Property:
●&nbsp;Many active grant applications: Currently Worksport is actively pursuing several multi-million-dollar grants to further support the business, research and development efforts, and sales efforts. Worksport will be excited to share updates in the coming months regarding some of these applications.
●&nbsp;Expanding IP Portfolio: The strength of Worksport's intellectual property portfolio continues to further solidify our market position and innovation capacity, with new additions to the portfolio every quarter for the last year.
Despite a stock price that does not reflect our true value, the company believes 2024 is set to be an inflection point for Worksport that solidifies our position as a U.S-based manufacturer dedicated to developing innovative hybrid and clean energy solutions in the light truck, overlanding, and global consumer goods markets.

WKSP

Worksport Issues Company Memo, Signals Undervalued Status, Eyes Major 2024 Growth

Visa to streamline access to select services via the AWS partner network for its cloud-native fintech, financial institution, and enterprise clients
Visa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>), a world leader in global digital payments, announced today it has joined the AWS Partner Network (APN), a global community that leverages AWS technologies, programs, expertise, and tools to build solutions and services for customers. Visa's presence in the APN will help enable its partners and clients, including cloud-native fintechs, to access and integrate select Visa services more efficiently.
Global Payments Simplified
Visa is committed to making transactions faster, easier and more secure for all players in the payments ecosystem. Visa will make select payment services available in the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Faws.amazon.com%2Fmarketplace%2F&amp;esheet=53956845&amp;newsitemid=20240425648724&amp;lan=en-US&amp;anchor=AWS+Marketplace&amp;index=1&amp;md5=333e4db72dfb5e8bdd8f833c37b5920f">AWS Marketplace</a>, which has more than 300,000 global customers and thousands of software listings.
By making its services available in AWS, Visa is meeting its clients where they are. One of the first services to be available is <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fusa.visa.com%2Fsolutions%2Fvisa-cross-border-solutions.html&amp;esheet=53956845&amp;newsitemid=20240425648724&amp;lan=en-US&amp;anchor=Visa+Cross-Border+Solutions&amp;index=2&amp;md5=14c2ac3b9e9b2d4bb4fea523d008d1b8">Visa Cross-Border Solutions</a>, which assists in streamlining the process of sending and receiving money globally and holding multiple currencies. This strategic positioning will allow Visa's clients to integrate solutions like Visa Cross-Border Solutions into their business operations - eliminating the need for them to step out of their established platforms.
"Visa is dedicated to better serving our clients in cloud environments, which is why we're excited to bring Visa Cross-Border Solutions to the AWS Marketplace," said Vanessa Colella, Global Head of Innovation and Digital Partnerships, Visa. "We aim to make our solutions readily accessible and available for customers to easily integrate across diverse platforms. This is a step further in our broader commitment to reduce challenges for financial institutions and enterprises."
Cloud-Based Connectivity
Through AWS, Visa plans to bring more of its products to clients operating in the cloud. Companies wanting to process payments through AWS on <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fcorporate.visa.com%2Fen%2Fabout-visa%2Fvisanet.html&amp;esheet=53956845&amp;newsitemid=20240425648724&amp;lan=en-US&amp;anchor=VisaNet&amp;index=3&amp;md5=65924159146fed437711573c9cea57ba">VisaNet</a>, Visa's global processing network, can already establish secure AWS Privatelink connectivity with <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fusa.visa.com%2Fproducts%2Fvisa-cloud-connect.html&amp;esheet=53956845&amp;newsitemid=20240425648724&amp;lan=en-US&amp;anchor=Visa+Cloud+Connect&amp;index=4&amp;md5=71e9dc0a0f8776cd99448f1c6aa44615">Visa Cloud Connect</a>.
Cloud-native fintechs, financial institutions, and enterprises have found using cloud services can help accelerate service deployment and customer adoption. It can also contribute to lowering costs associated with local data centers, implementing specialized hardware like physical routers, and payment hardware security modules (HSMs).
"As a cloud-native card issuer and processor, and one of the first issuer processors in Europe to connect to the Visa Cloud Connect endpoint in the EU, we believe the enablement of Visa services through AWS is a gamechanger," said Merusha Naidu, Global Head of Partnerships, Paymentology. "This partnership paves the way for enhanced digital payment solutions, providing startups with the tools they need to innovate and thrive in today's fast-paced landscape."
Empowering Startups with Fintech Solutions
Visa is also proud to announce that it is now part of <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Faws.amazon.com%2Factivate%2Factivate-landing%2F&amp;esheet=53956845&amp;newsitemid=20240425648724&amp;lan=en-US&amp;anchor=AWS+Activate&amp;index=5&amp;md5=cc43861259d18dfd725af01cdf48c54e">AWS Activate</a>, AWS's flagship startup program. Fintech clients enrolled in the Visa <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fpartner.visa.com%2Fsite%2Fprograms%2Ffintech-program.html&amp;esheet=53956845&amp;newsitemid=20240425648724&amp;lan=en-US&amp;anchor=Fintech+Fast+Track+program&amp;index=6&amp;md5=c9fbd246968dcbc8412c3ff3e7109b07">Fintech Fast Track program</a>, and verified by AWS as eligible, can receive up to $100,000 in AWS Activate credits to help jumpstart their growth and reduce their time to market.
"We are excited to support the expansion of digital payments, banking, and embedded finance capabilities to enterprises and fintech startups building their applications on AWS," said Howard Wright, VP and Global Head of Startups at AWS. "We are looking forward to working with Visa to help make financial apps in the cloud more accessible, faster, secure, and easier to use."
Many startups running on AWS have already benefited from Visa programs like <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fpartner.visa.com%2Fsite%2Fprograms%2Fvisa-ready.html&amp;esheet=53956845&amp;newsitemid=20240425648724&amp;lan=en-US&amp;anchor=Visa+Ready&amp;index=7&amp;md5=476237ec92741dc666d4fd2e8177e583">Visa Ready</a> and Fintech Fast Track.

AMZN

Visa Joins AWS Partner Network To Help Simplify Global Digital Payments

Guidance
Hess Midstream continues to target at least&nbsp;5%&nbsp;annual distribution growth per Class A share through 2026 from this new higher level and continues to prioritize financial strength with a long-term leverage target of 3x Adjusted EBITDA. For 2025 and 2026, Hess Midstream continues to expect organic throughput volume growth across all systems relative to 2024 volume&nbsp;guidance.
Hess Midstream is reaffirming its full year 2024&nbsp;guidance&nbsp;as follows:
<table cellspacing="0">
<tbody>
<tr>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="2" rowspan="1">
Year Ending
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="2" rowspan="1">
December 31, 2024
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="2" rowspan="1">
(Unaudited)
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Financials (in millions)
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Net income
</td>
<td colspan="1" rowspan="1">
$
</td>
<td colspan="1" rowspan="1">
670 - 720
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Adjusted EBITDA
</td>
<td colspan="1" rowspan="1">
$
</td>
<td colspan="1" rowspan="1">
1,125 - 1,175
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Capital expenditures
</td>
<td colspan="1" rowspan="1">
$
</td>
<td colspan="1" rowspan="1">
250 - 275
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Adjusted free cash flow
</td>
<td colspan="1" rowspan="1">
$
</td>
<td colspan="1" rowspan="1">
685 - 735
</td>
</tr>
</tbody>
</table>

HESM

Hess Midstream Reaffirms 2024 Guidance For Net Income Of $670M - $720M, Adjusted EBITDA Of $1.125B – $1.175B And Adjusted Free Cash Flow Of $685M - $735M; Continues To Target At Least 5% Annual Distribution Growth Per Class A Share Through 2026

2024&nbsp;Guidance&nbsp;Remains Unchanged
<ul>
<li>2024 Full-year average production of 35,500-39,000 boepd, as announced on February 21, 2024</li>
<li>Fully-funded 2024 organic capital expenditures program of&nbsp;$150-200 million to drill 35-45 gross wells (including 5-10 gross exploration wells and 30-35 gross appraisal and development wells)</li>
</ul>

General

GPRK

Geopark Reports 1Q 2024 Average Oil And Gas Production Of 35,473 Boe/Day

<ul>
<li>Upadacitinib demonstrated superiority versus dupilumab in primary endpoint of simultaneous achievement of near complete skin clearance (EASI 90) and no to little itch (WP-NRS 0/1) at Week 161</li>
<li>LEVEL UP, a Phase 3b/4 head-to-head study, compared upadacitinib to dupilumab for the treatment of adult and adolescent patients with moderate-to-severe atopic dermatitis who had inadequate response to systemic therapy or when use of those therapies was inadvisable1</li>
<li>The safety profile of upadacitinib was consistent with the profile in previous atopic dermatitis studies with no new safety signals identified during the 16-week period1,2</li>
</ul>
NORTH CHICAGO, Ill., April 25, 2024 /PRNewswire/ --&nbsp;AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) today announced positive topline results from LEVEL UP, an open-label, efficacy assessor-blinded head-to-head Phase 3b/4&nbsp;study that evaluated the efficacy and safety of upadacitinib (RINVOQ&#xAE;, 15 mg once daily starting dose and dose-adjusted based on clinical response) versus dupilumab (DUPIXENT&#xAE;, per its labeled dose) in adults and adolescents (≥12 years of age) with moderate-to-severe atopic dermatitis (AD) who had an inadequate response to systemic therapy or when use of those therapies was inadvisable.
"Even while receiving conventional treatments, many patients with atopic dermatitis still continue to live with&nbsp;significant itch&nbsp;and inflammatory skin symptoms that can profoundly impact their everyday lives," said&nbsp;Roopal Thakkar, M.D., senior vice president, chief medical officer, global therapeutics, AbbVie. "Results from this study show that patients with moderate-to-severe atopic dermatitis can strive for both little to no itch and clearer skin."
In the LEVEL UP study,&nbsp;upadacitinib showed superior efficacy versus dupilumab in the primary endpoint, demonstrating that a significantly higher proportion of patients simultaneously achieved both a 90% or greater reduction in Eczema Area and Severity Index (EASI 90) and a Worst Pruritus Numerical Rating Scale of 0 or 1 (WP-NRS 0/1) at Week 16 [(19.9% vs 8.9% for upadacitinib and dupilumab respectively, p&lt;0.0001)].1
The EASI is a clinically validated measure used to assess the severity and extent of atopic dermatitis, while the WP-NRS is an assessment tool that patients use to report the intensity of their pruritus daily (with 0 being 'no itch' and 10 being the 'worst imaginable itch').
Upadacitinib also showed superiority versus dupilumab for all ranked secondary endpoints, including the rapid onset of achieving near complete skin clearance and no to little itch.&nbsp;For the first two ranked secondary endpoints, the study showed that&nbsp;a significantly higher proportion of patients treated with upadacitinib:
<ul>
<li>Achieved EASI 90 at Week 16 [(40.8% vs 22.5%, p&lt;0.0001)].1</li>
<li>Achieved a WP-NRS of 0/1 at Week 16 [(30.2% vs 15.5%, p&lt;0.0001)].1,a</li>
</ul>
AbbVie plans to present results from the LEVEL UP study at a future medical congress.
The LEVEL UP study is the first head-to-head trial in atopic dermatitis assessing upadacitinib at a starting&nbsp;dose of 15 mg daily versus dupilumab at its labeled dose. Upadacitinib was initiated in adults and adolescents (≥12 years of age, weighing at least 40 kg) at 15 mg once daily (QD) and dose-escalated to 30 mg QD based on clinical response. Dupilumab was initiated at 600 mg, followed by 300 mg every other week (Q2W) in adults and adolescents weighing ≥60 kg; adolescents weighing less than 60 kg received an initial dose of 400 mg, followed by 200 mg Q2W.1
"Too many patients are still not achieving optimal disease control in atopic dermatitis despite taking steps to manage their condition," said&nbsp;Jonathan Silverberg, M.D., Ph.D., MPH, professor of dermatology and director of clinical research at the George Washington University School of Medicine and Health Sciences. "Results from the LEVEL UP study highlight how treatment options such as upadacitinib can achieve high treatment goals in atopic dermatitis with combined measures of EASI 90 and NRS 0/1, not just itch resolution or just skin clearance."
The observed safety profile for upadacitinib in LEVEL UP was consistent with that observed in previous upadacitinib atopic dermatitis clinical studies.1,2 No new safety signals were identified during the study period.1 In Period 1, the most common adverse events&nbsp;(AE) reported were nasopharyngitis&nbsp;for both the upadacitinib and dupilumab group.1 The rate of serious AEs (0.9%) was the same for both upadacitinib and dupilumab. There was one serious infection reported in the dupilumab group and none in the upadacitinib group.1&nbsp;No malignancies, adjudicated major adverse cardiac events, adjudicated venous thromboembolic events (VTEs)&nbsp;or treatment-emergent deaths were reported in either treatment group.1
[a]&nbsp;This endpoint was evaluated among patients with a baseline WP-NRS &gt;1.
About Atopic Dermatitis&nbsp;

Biotech

ABBV

AbbVie New Data Show RINVOQ Demonstrated Superiority Versus DUPIXENT Across Primary And All Secondary Endpoints In An Open-Label Head-To-Head Atopic Dermatitis Study; Achieved Both A 90% Or Greater Reduction In Eczema Area And Severity Index And A Worst Pruritus Numerical Rating Scale Of 0 Or 1 At Week 16

West Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTBA#NASDAQ">WTBA</a>) reported quarterly earnings of $0.35 per share which beat the analyst consensus estimate of $0.27 by 29.63 percent. This is a 25.53 percent decrease over earnings of $0.47 per share from the same period last year. The company reported quarterly sales of $19.049 million which beat the analyst consensus estimate of $18.890 million by 0.84 percent. This is a 12.02 percent decrease over sales of $21.652 million the same period last year.

WTBA

West Bancorp Q1 2024 GAAP EPS $0.35 Beats $0.27 Estimate, Sales $19.049M Beat $18.890M Estimate

ShareCap calls on the Board to initiate a strategic alternatives process that, among the alternatives, reconsiders Future Pak&#39;s offer.

VNDA

Vanda Pharmaceuticals Shareholder ShareCap Says Company Board Must Explore Strategic Alternatives

T-Mobile US, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) is set to release earnings results for its first quarter, after the <a href="https://www.benzinga.com/quote/TMUS/earnings">closing bell on April 25, 2024.</a>
Analysts expect the Bellevue, Washington-based company to report quarterly earnings at $1.87 per share, up from $1.58 per share in the year-ago period. T-Mobile US is projected to post revenue of $19.81 billion (roughly the same as the year-earlier quarter, per data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>).
T-Mobile recently announced $163 Million in completed network upgrades for Arkansas.
With the recent buzz around T-Mobile US, some investors may be eyeing potential gains from the company's dividends, too. T-Mobile US currently offers an annual dividend yield of 1.58% — a quarterly dividend amount of 65 cents per share ($2.60 a year).
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $378,927 or around 2,308 shares. For a more modest $100 per month or $1,200 per year, you would need $75,851 or around 462 shares.
Read This: <a href="https://www.benzinga.com/news/24/04/38402061/jim-cramer-says-this-energy-stock-is-terrific-calls-caseys-general-stores-a-winner">Jim Cramer Says This Energy Stock Is &#8216;Terrific,&#8217; Calls Casey&#8217;s General Stores A &#8216;Winner&#8217;</a>
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($2.60 in this case). So, $6,000 / $2.60 = 2,308 ($500 per month), and $1,200 / $2.60 = 462 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
TMUS Price Action: Shares of T-Mobile US rose 0.6% to close at $164.18 on Wednesday.
Read More: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/04/38405528/over-1m-bet-on-citi-trends-check-out-these-3-stocks-insiders-are-buying">Over $1M Bet On Citi Trends? Check Out These 3 Stocks Insiders Are Buy</a><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/04/38405528/over-1m-bet-on-citi-trends-check-out-these-3-stocks-insiders-are-buying">ing</a>
Image: Shutterstock

Long Ideas

TMUS

How To Earn $500 A Month From T-Mobile US Stock Ahead Of Q1 Earnings Report

ROIV

Roivant And Kinevant Sciences Complete Enrollment In RESOLVE-Lung Phase 2 Study Evaluating Namilumab For Chronic Pulmonary Sarcoidosis

Standard BioTools Expects To Achieve $45M-$50M In Annualized Operating Expense Savings In Fiscal 2025

Telsey Advisory Group analyst Sarang Vora maintains Coursera (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COUR#NYSE">COUR</a>) with a Outperform and maintains $25 price target.

COUR

Telsey Advisory Group Maintains Outperform on Coursera, Maintains $25 Price Target

Pasithea stock soars as high as 190% on preclinical data

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pasithea Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ktta-stock-quote/">KTTA</a>) stock is rocketing higher on Monday after the biotechnology company announced results from <a href="https://finance.yahoo.com/news/pasithea-therapeutics-announces-positive-vivo-130100020.html">two preclinical trials of PAS-004</a>.



The first study saw positive results from PAS-004 as a treatment for lung cancer. The in vivo study showed efficiency in inhibiting tumor growth from the NCI-H1299 cell-line-derived xenograft model.



The in vivo study second study showed PAS-004 as an effective treatment for liver cancer. This saw it perform well with anti-tumor activities against the xHepG2 cell-line-derived xenograft model.



Dr. Graeme Currie, Chief Development Officer of Pasithea Therapeutics, said the following about these results.




&ldquo;Our current modeling suggests we will have a longer half-life in humans than existing MEK inhibitors and when coupled with our preclinical profile, we believe a once-a-day or less frequent dosing regimen is likely to be achieved for PAS-004, which we hope will lead to improved compliance when compared to existing therapies, as well as better combinability with other cancer agents.&rdquo;




<h2>How This Affects KTTA Stock Today</h2>



News of these positive studies brings with them heavy trading for KTTA stock on Monday. As of this writing, more than 80 million shares of the stock have changed hands. That&rsquo;s a massive trading volume compared to Pasithea Therapeutics&rsquo; daily average of just 39,000 shares.



KTTA stock is up 104.9% as of Monday morning.



Investors can find more of the latest stock market news ready to go below!



We have all of the most recent stock market news worth reading about on Monday! A few examples include what&rsquo;s happening with shares of Sea Limited&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/se-stock-quote/">SE</a>), Macy&rsquo;s&nbsp;(NYSE:<a href="https://investorplace.com/cryptocurrency/m/">M</a>) and Qudian&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/qd-stock-quote/">QD</a>) stock today. All of that news is ready to go at the following links!



<h2>More Monday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2023/12/why-is-sea-limited-se-stock-down-today/">Why Is Sea Limited (SE) Stock Down Today?</a></li>



<li><a href="https://investorplace.com/2023/12/5-investors-betting-big-on-macys-m-stock/">5 Investors Betting Big on Macy&rsquo;s (M) Stock</a></li>



<li><a href="https://investorplace.com/earning-results/2023/12/qd-stock-earnings-qudian-for-q3-of-2023/">QD Stock Earnings: Qudian Reported Results for Q3 2023</a></li>
</ul>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.



With only the rarest exceptions,&nbsp;InvestorPlace&nbsp;does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;<a href="https://investorplace.com/stock-types/penny-stocks/">penny stocks</a>&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;&nbsp;<a href="http://investorplace.com/" target="_blank">InvestorPlace.com</a>&rsquo;s&nbsp;writers disclose this fact and warn readers of the risks.&nbsp;



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/venture-capitalist-predicts-this-chatgpt-announcement-will-shock-the-world/?cid=MKT744191&amp;eid=MKT766413">ChatGPT IPO Could Shock the World, Make This Move Before the Announcement</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/05/secret-income-blueprint-of-the-one-percent/?cid=MKT730394&amp;eid=MKT766529">The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2023/12/why-is-pasithea-therapeutics-ktta-stock-up-105-today/">Why Is Pasithea Therapeutics (KTTA) Stock Up 105% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Pasithea Therapeutics (KTTA) Stock Up 105% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Checking out the biggest pre-market stock movers for Tuesday is the perfect way to get ready for another busy day of trading!



Moving stocks this morning are an acquisition deal, clinical trial updates and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>SRIVARU Holding (NASDAQ:<a href="https://investorplace.com/stock-quotes/svmhw-stock-quote/">SVMHW</a>) stock is rocketing more than 142% on Tuesday morning.</li>



<li>Icosavax (NASDAQ:<a href="https://investorplace.com/stock-quotes/icvx-stock-quote/">ICVX</a>) shares are soaring over 45% on news of <a href="https://www.nasdaq.com/press-release/astrazeneca-to-acquire-icosavax-including-potential-first-in-class-rsv-and-hmpv">an acquisition deal with AstraZeneca</a> (NASDAQ:<a href="https://investorplace.com/stock-quotes/azn-stock-quote/">AZN</a>).</li>



<li>Bruush Oral Care (NASDAQ:<a href="https://investorplace.com/stock-quotes/brsh-stock-quote/">BRSH</a>) stock is surging more than 44% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=317920394&amp;type=PDF&amp;symbol=BRSH&amp;cdn=d35ab767736c666b8c5cc03391eae5d3&amp;companyName=Bruush+Oral+Care+Inc.&amp;formType=6-K&amp;formDescription=Report+of+foreign+private+issuer+pursuant+to+Rule+13a-16+or+15d-16+under+the+Securities+Exchange+Act+of+1934&amp;dateFiled=2023-12-11">on a delisting update</a>.</li>



<li>Hanryu (NASDAQ:<a href="https://investorplace.com/stock-quotes/hryu-stock-quote/">HRYU</a>) shares are increasing over 26% on Tuesday.</li>



<li>IN8bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/inab-stock-quote/">INAB</a>) stock is rising more than 22% on a <a href="https://www.nasdaq.com/press-release/in8bio-announces-positive-clinical-update-demonstrating-continued-durable-complete">Phase 1 clinical trial update</a>.</li>



<li>Connect Biopharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/cntb-stock-quote/">CNTB</a>) shares are gaining over 21% alongside <a href="https://www.nasdaq.com/press-release/connect-biopharma-announces-positive-rademikibart-global-phase-2b-topline-results-in">Phase 2 clinical trial results</a>.</li>



<li>Gravitas Education (NYSE:<a href="https://investorplace.com/stock-quotes/gehi-stock-quote/">GEHI</a>) stock is climbing more than 19% after <a href="https://www.nasdaq.com/press-release/gravitas-education-holdings-inc.-announces-expected-timing-for-the-effective-time-of">announcing merger timing</a>.</li>



<li>Oncternal Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/onct-stock-quote/">ONCT</a>) shares are heading over 17% higher this morning.</li>



<li>NFT Gaming Co (NASDAQ:<a href="https://investorplace.com/stock-quotes/nftg-stock-quote/">NFTG</a>) stock is jumping more than 16% today.</li>



<li>Senti Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/snti-stock-quote/">SNTI</a>) shares are up over 15% on Tuesday morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Harbor Custom Development&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/hcdi-stock-quote/">HCDI</a>) stock is diving more than 30% after filing for <a href="https://www.nasdaq.com/press-release/harbor-custom-development-inc.-announces-chapter-11-bankruptcy-protection-filing-2023">Chapter 11 bankruptcy protection</a>.</li>



<li>Achieve Life Sciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/achv-stock-quote/">ACHV</a>) shares are tumbling over 19% on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=317919685&amp;type=PDF&amp;symbol=ACHV&amp;cdn=62713ed140b0e1c470a2598722927a40&amp;companyName=Achieve+Life+Sciences+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2023-12-11">new drug application update</a>.</li>



<li>InMed Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/inm-stock-quote/">INM</a>) stock is taking an 18% beating this morning.</li>



<li>Altamira Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cyto-stock-quote/">CYTO</a>) shares are dropping more than 16% <a href="https://www.globenewswire.com/news-release/2023/12/11/2793828/0/en/Altamira-Therapeutics-Provides-Investor-and-Business-Update.html">following an investor update</a>.</li>



<li>Assure (NASDAQ:<a href="https://investorplace.com/stock-quotes/ionm-stock-quote/">IONM</a>) stock is decreasing over 15% on Tuesday morning.</li>



<li>Nexalin Technology (NASDAQ:<a href="https://investorplace.com/stock-quotes/nxl-stock-quote/">NXL</a>) shares are falling more than 14% today.</li>



<li>Pasithea Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ktta-stock-quote/">KTTA</a>) stock is declining over 12% <a href="https://investorplace.com/2023/12/why-is-pasithea-therapeutics-ktta-stock-up-105-today/">following a rally yesterday</a>.</li>



<li>African Agriculture (NASDAQ:<a href="https://investorplace.com/stock-quotes/aagr-stock-quote/">AAGR</a>) shares are sliding more than 12% as it continues recent negative movement.</li>



<li>CareCloud (NASDAQ:<a href="https://investorplace.com/stock-quotes/ccld-stock-quote/">CCLD</a>) stock is dipping over 12% after <a href="https://www.nasdaq.com/press-release/carecloud-announces-suspension-of-its-dividends-on-non-convertible-series-a-and">suspending its dividends</a>.</li>



<li>Clearmind Medicine (NASDAQ:<a href="https://investorplace.com/stock-quotes/cmnd-stock-quote/">CMND</a>) shares close out our pre-market stock movers down more than 11% on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=317920483&amp;type=PDF&amp;symbol=CMND&amp;cdn=79b8c1d0ca22db6346a7ced30f096de7&amp;companyName=Clearmind+Medicine+Inc.&amp;formType=F-3&amp;formDescription=Registration+statement+for+securities+of+certain+foreign+private+issuers&amp;dateFiled=2023-12-11">proposed stock offering</a>.</li>
</ol>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771234">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771244">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/05/secret-income-blueprint-of-the-one-percent/?cid=MKT730394&amp;eid=MKT771242">The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2023/12/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-dec-12th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are a hot topic on Wednesday and we&rsquo;re starting the day with a breakdown of the biggest ones worth watching!



Moving stocks this morning are clinical trial news, an earnings report and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>RiskOn International (NASDAQ:<a href="https://investorplace.com/stock-quotes/roi-stock-quote/">ROI</a>) stock is rocketing more than 59% alongside insider buying.</li>



<li>Innovative International (NASDAQ:<a href="https://investorplace.com/stock-quotes/ioac-stock-quote/">IOAC</a>) shares are soaring over 42% after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=317922105&amp;type=PDF&amp;symbol=IOACU&amp;cdn=8c06e942afe7500becaba0a1d26b274b&amp;companyName=Innovative+International+Acquisition+Corp.+Unit&amp;formType=DEFA14A&amp;formDescription=Additional+proxy+soliciting+materials+-+definitive&amp;dateFiled=2023-12-12">announcing a shareholder meeting date</a>.</li>



<li>Reshape Lifesciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/rsls-stock-quote/">RSLS</a>) stock is surging more than 35% alongside <a href="https://www.nasdaq.com/press-release/reshape-lifesciencesr-receives-fda-pma-supplement-approval-for-its-next-generation">Food and Drug Administration (FDA) approval</a>.</li>



<li>Shattuck Labs (NASDAQ:<a href="https://investorplace.com/stock-quotes/sttk-stock-quote/">STTK</a>) shares are gaining over 24% with the <a href="https://www.nasdaq.com/press-release/shattuck-labs-announces-positive-initial-topline-data-from-ongoing-phase-1-a-b-dose">release of clinical trial data</a>.</li>



<li>Mynaric (NASDAQ:<a href="https://investorplace.com/stock-quotes/myna-stock-quote/">MYNA</a>) stock is increasing more than 16% after <a href="https://www.nasdaq.com/press-release/mynaric-receives-us-%2433-million-order-from-northrop-grumman-2023-12-13">getting a $33 million order</a>.</li>



<li>CISO Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/ciso-stock-quote/">CISO</a>) shares are rising close to 15% on Wednesday morning.</li>



<li>Carbon Revolution (NASDAQ:<a href="https://investorplace.com/stock-quotes/crev-stock-quote/">CREV</a>) stock is climbing over 14% <a href="https://finance.yahoo.com/news/carbon-revolution-provides-business-210500696.html">alongside a business update</a>.</li>



<li>Ault Alliance (NYSEMKT:<a href="https://investorplace.com/stock-quotes/ault-stock-quote/">AULT</a>) shares are heading more than 14% higher after <a href="https://www.nasdaq.com/press-release/ault-alliance-reiterates-its-intention-to-commence-an-exchange-offer-of-common-stock">confirming plans for a share offering</a>.</li>



<li>LifeMD (NASDAQ:<a href="https://investorplace.com/stock-quotes/lfmd-stock-quote/">LFMD</a>) stock is jumping over 13% after <a href="https://www.nasdaq.com/press-release/medifast-initiates-business-transformation-by-entering-the-medically-supported-weight">announcing a business transformation</a>.</li>



<li>C4 Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cccc-stock-quote/">CCCC</a>) shares are up more than 12% as it <a href="CCCC">continues its recent rally</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Loop Media (NYSEMKT:<a href="https://investorplace.com/stock-quotes/lptv-stock-quote/">LPTV</a>) stock is diving over 19% after <a href="https://www.nasdaq.com/press-release/loop-media-reports-full-year-2023-and-fourth-quarter-fiscal-financial-results-2023-12">missing its latest earnings estimates</a>.</li>



<li>Shengfeng Development (NASDAQ:<a href="https://investorplace.com/stock-quotes/sfwl-stock-quote/">SFWL</a>) shares are tumbling more than 13% without any clear news this morning.</li>



<li>Edesa Biotech (NASDAQ:<a href="https://investorplace.com/stock-quotes/edsa-stock-quote/">EDSA</a>) stock is taking an over 12% beating on Wednesday morning.</li>



<li>Altisource Asset Management (NYSEMKT:<a href="https://investorplace.com/stock-quotes/aamc-stock-quote/">AAMC</a>) shares are sliding more than 12% this morning.</li>



<li>Pasithea Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ktta-stock-quote/">KTTA</a>) stock is dropping over 11% <a href="https://investorplace.com/2023/12/why-is-pasithea-therapeutics-ktta-stock-up-105-today/">following study news yesterday</a>.</li>



<li>VS Media (NASDAQ:<a href="https://investorplace.com/stock-quotes/vsme-stock-quote/">VSME</a>) shares are decreasing nearly 11% on Wednesday morning.</li>



<li>Mobilicom (NASDAQ:<a href="https://investorplace.com/stock-quotes/mob-stock-quote/">MOB</a>) stock is falling almost 11% <a href="https://www.nasdaq.com/press-release/mobilicom-chosen-by-the-u.s.-department-of-defense-for-soldiers-next-generation">following a rally yesterday</a>.</li>



<li>Inpixon (NASDAQ:<a href="https://investorplace.com/stock-quotes/inpx-stock-quote/">INPX</a>) shares are declining more than 10% following <a href="https://www.nasdaq.com/press-release/inpixon-announces-shareholder-approval-of-proposals-related-to-merger-agreement-with">approval for a merger</a>.</li>



<li>SRIVARU Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVMH#NASDAQ">SVMH</a>) stock is slipping over 9% this morning.</li>



<li>IN8bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/inab-stock-quote/">INAB</a>) shares close out our pre-market stock movers down close to 9% <a href="https://investorplace.com/2023/12/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-dec-12th/">after rallying yesterday</a>.</li>
</ol>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/05/secret-income-blueprint-of-the-one-percent/?cid=MKT730394&amp;eid=MKT771243">The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2023/12/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-dec-13th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pasithea Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ktta-stock-quote/">KTTA</a>) stock is falling on Wednesday after the company&rsquo;s shares experienced major volatility on Tuesday.



Investors watching KTTA stock will note that it closed out Tuesday up less than 1%. However, in earlier trading that day the stock saw <a href="https://investorplace.com/2023/12/why-is-pasithea-therapeutics-ktta-stock-up-105-today/">gains of more than 100%</a>.



So what happened?



Pasithea Therapeutics saw its shares rally in early morning trading on Tuesday alongside results from two preclinical trials. That came with heavy trading pushing the shares higher. However, it was unable to maintain that increased price.



It&rsquo;s possible that this has to do with KTTA being a penny stock. That opens it up to vulnerabilities, such as extreme volatility. It could be that day traders latched onto the stock yesterday alongside the study news and then sold their shares when prices peaked.



<h2>KTTA Stock Movement on Wednesday</h2>



As for KTTA stock movement today, the company&rsquo;s shares are down 11.8% during pre-market trading on Wednesday. That comes as some 31,000 shares change hands, as compared to its daily average of about 1.7 million shares.



Investors seeking out even more of the most recent stock market stories will want to stick around!



We have all of the hottest stock market news worth reading about on Wednesday! That includes everything happening with shares of Loop Media&nbsp;(NYSEMKT:<a href="https://investorplace.com/stock-quotes/lptv-stock-quote/">LPTV</a>) stock, Innovative International&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ioac-stock-quote/">IOAC</a>) stock and RiskOn International&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/roi-stock-quote/">ROI</a>) stock this morning. All of that news is available at the following links!



<h2>More Stock Market News for Wednesday</h2>



<ul><li><a href="https://investorplace.com/2023/12/why-is-loop-media-lptv-stock-down-16-today/">Why Is Loop Media (LPTV) Stock Down 16% Today?</a></li>



<li><a href="https://investorplace.com/2023/12/why-is-innovative-international-ioac-stock-up-31-today/">Why Is Innovative International (IOAC) Stock Up 31% Today?</a></li>



<li><a href="https://investorplace.com/2023/12/why-is-riskon-international-roi-stock-up-28-today/">Why Is RiskOn International (ROI) Stock Up 28% Today?</a></li>
</ul>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.



With only the rarest exceptions,&nbsp;InvestorPlace&nbsp;does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;<a href="https://investorplace.com/stock-types/penny-stocks/">penny stocks</a>&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;&nbsp;<a href="http://investorplace.com/" target="_blank">InvestorPlace.com</a>&rsquo;s&nbsp;writers disclose this fact and warn readers of the risks.&nbsp;



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771234">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771244">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/05/secret-income-blueprint-of-the-one-percent/?cid=MKT730394&amp;eid=MKT771242">The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2023/12/why-is-pasithea-therapeutics-ktta-stock-down-12-today/">Why Is Pasithea Therapeutics (KTTA) Stock Down 12% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Pasithea Therapeutics (KTTA) Stock Down 12% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
ReShape Lifesciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/rsls-stock-quote/">RSLS</a>) stock is rising higher on Wednesday following approval from the Food and Drug Administration (FDA) for <a href="https://finance.yahoo.com/news/reshape-lifesciences-receives-fda-pma-210500500.html">a PMA supplement</a>.



That a PMA supplement applies to the company&rsquo;s Lap-Band 2.0 FLEX. This is the company&rsquo;s minimally invasive, long-term treatment of obesity.



Paul Hickey, president and CEO of ReShape Lifesciences, explains the differences the come with its updated Lap-Band 2.0 FLEX product.




&ldquo;Compared to our current Lap-Band, the Lap-Band&reg; 2.0 has a new feature called FLEX Technology, which acts as a relief valve, allowing larger pieces of food to more easily pass through the narrowed passage (or stoma), created by the band. Specifically, the band momentarily relaxes before returning to its resting diameter, therefore, minimizing discomfort caused by passage of large food pieces through the stoma.&rdquo;




<h2>What This Means for RSLS Stock</h2>



Improvement of its weight loss product is a positive for ReShape Lifesciences. The FDA approval also allows puts it closer to market, which could mean more revenue for the company.



With this news comes heavy trading of RSLS stock. As of this writing, around 50 million shares have changed hands. That&rsquo;s a massive leap in trading volume compared to the company&rsquo;s daily average of about 4 million shares.



RSLS stock is up 67.7% as of Wednesday morning.



There&rsquo;s more stock market news worth reading about below!



We have all of the hottest stock market news traders need to know about on Wednesday! Among that is what&rsquo;s happening with shares of Pasithea Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ktta-stock-quote/">KTTA</a>), Loop Media&nbsp;(NYSEMKT:<a href="https://investorplace.com/stock-quotes/lptv-stock-quote/">LPTV</a>)&nbsp;and Innovative International&nbsp;Acquisition&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ioac-stock-quote/">IOAC</a>) stock. You can find out more on these matters down below!



<h2>More Wednesday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2023/12/why-is-pasithea-therapeutics-ktta-stock-down-12-today/">Why Is Pasithea Therapeutics (KTTA) Stock Down 12% Today?</a></li>



<li><a href="https://investorplace.com/2023/12/why-is-loop-media-lptv-stock-down-16-today/">Why Is Loop Media (LPTV) Stock Down 16% Today?</a></li>



<li><a href="https://investorplace.com/2023/12/why-is-innovative-international-ioac-stock-up-31-today/">Why Is Innovative International (IOAC) Stock Up 31% Today?</a></li>
</ul>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.



With only the rarest exceptions,&nbsp;InvestorPlace&nbsp;does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;<a href="https://investorplace.com/stock-types/penny-stocks/">penny stocks</a>&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;&nbsp;<a href="http://investorplace.com/" target="_blank">InvestorPlace.com</a>&rsquo;s&nbsp;writers disclose this fact and warn readers of the risks.&nbsp;



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771234">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771244">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/05/secret-income-blueprint-of-the-one-percent/?cid=MKT730394&amp;eid=MKT771242">The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2023/12/why-is-reshape-lifesciences-rsls-stock-up-68-today/">Why Is ReShape Lifesciences (RSLS) Stock Up 68% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is ReShape Lifesciences (RSLS) Stock Up 68% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Palantir Technologies (NYSE:<a href="https://investorplace.com/stock-quotes/pltr-stock-quote/">PLTR</a>) stock is in the news Wednesday after the big data company <a href="https://finance.yahoo.com/news/palantir-renews-digital-transformation-partnership-115900977.html">renewed a contract</a> with UniCredit.



According to a press release from Palantir, UniCredit has renewed its partnership with the company for another five years. That will see it make use of the Palantir Foundry operating system to enhance its digital transformation.



Investors will note that Palantir and UniCredit first started working together in 2018. Over those five years, UniCredit saw significant benefits from the Palantir Foundry operating system. That even resulted in it expanding the use of the technology to all CE&amp;EE UniCredit Legal Entities.



Josh Harris, a Palantir executive, said the following about this partnership.




&ldquo;Palantir has long been a proud partner to some of the world&rsquo;s top financial institutions. We&rsquo;re honored that UniCredit has placed its confidence in Palantir once again and look forward to furthering the bank&rsquo;s digital transformation.&rdquo;




<h2>PLTR Stock Movement on Wednesday</h2>



With this recent news comes some 7 million shares of PLTR stock changing hands. That&rsquo;s still a ways off from its daily average trading volume of about 61 million shares. The stock is also down 1.3% as of Wednesday morning despite the renewed contract. However, PLTR is up 170.4% year-to-date.



Investors looking for more of the latest stock market news will want to keep reading!



We have all of the hottest stock market news worth checking out on Wednesday! A few examples of that include what&rsquo;s happening with ReShape Lifesciences&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/rsls-stock-quote/">RSLS</a>), Pasithea Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ktta-stock-quote/">KTTA</a>) and Loop Media&nbsp;(NYSEMKT:<a href="https://investorplace.com/stock-quotes/lptv-stock-quote/">LPTV</a>) stock. You can find more on these matters below!



<h2>More Wednesday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2023/12/why-is-reshape-lifesciences-rsls-stock-up-68-today/">Why Is ReShape Lifesciences (RSLS) Stock Up 68% Today?</a></li>



<li><a href="https://investorplace.com/2023/12/why-is-pasithea-therapeutics-ktta-stock-down-12-today/">Why Is Pasithea Therapeutics (KTTA) Stock Down 12% Today?</a></li>



<li><a href="https://investorplace.com/2023/12/why-is-loop-media-lptv-stock-down-16-today/">Why Is Loop Media (LPTV) Stock Down 16% Today?</a></li>
</ul>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771234">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771244">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/05/secret-income-blueprint-of-the-one-percent/?cid=MKT730394&amp;eid=MKT771242">The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2023/12/pltr-stock-palantir-renews-unicredit-partnership/">PLTR Stock: Palantir Renews UniCredit Partnership</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

PLTR Stock: Palantir Renews UniCredit Partnership

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Roblox (NYSE:<a href="https://investorplace.com/stock-quotes/rblx-stock-quote/">RBLX</a>) stock is on the move Wednesday as investors react to new coverage of the video game company&rsquo;s shares from Wells Fargo.



Wells Fargo analysts <a href="https://www.investing.com/news/stock-market-news/roblox-ads-to-become-significant-earnings-stream-over-time--wells-fargo-432SI-3255780">initiated coverage of RBLX stock</a> with an &ldquo;overweight&rdquo; rating. To put that in perspective, the analysts&rsquo; consensus rating for RBLX shares is moderate buy based on 22 opinions.



In addition to that, the company started its coverage of RBLX stock with a price target of $49 per share. That represents a potential upside of 16.6%. It&rsquo;s also bullish next to the analysts&rsquo; consensus price prediction of <a href="https://www.marketbeat.com/stocks/NYSE/RBLX/price-target/">$41.62 per share</a>.



<h2>Why the Bull Rating for RBLX Stock?</h2>



Here&rsquo;s what the Wells Fargo analysts had to say about Roblox in a note to clients obtained by Investing.com.




&ldquo;Similar to other audience platforms, we expect ads to become a significant earnings stream over time for Roblox, supported by strong user engagement. See meaningful upside to consensus bookings and EBITDA as we believe the ads opportunity is underappreciated by the Street, which has yet to properly capture future ad bookings into forecasts.&rdquo;




RBLX stock is up 2.5% as of Wednesday morning. This comes with more than 3.8 million shares traded. For the record, the company&rsquo;s daily average trading volume is still above that at 10.5 million shares.



Investors who want more of the latest stock market news are in luck!



We&rsquo;ve got all of the hottest stock market stories that traders need to know about on Wednesday! That includes everything going on with Palantir Technologies&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/pltr-stock-quote/">PLTR</a>) stock, ReShape Lifesciences&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/rsls-stock-quote/">RSLS</a>) stock and Pasithea Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ktta-stock-quote/">KTTA</a>) stock. You can find out more on these matters at the following links!



<h2>More Wednesday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2023/12/pltr-stock-palantir-renews-unicredit-partnership/">PLTR Stock: Palantir Renews UniCredit Partnership</a></li>



<li><a href="https://investorplace.com/2023/12/why-is-reshape-lifesciences-rsls-stock-up-68-today/">Why Is ReShape Lifesciences (RSLS) Stock Up 68% Today?</a></li>



<li><a href="https://investorplace.com/2023/12/why-is-pasithea-therapeutics-ktta-stock-down-12-today/">Why Is Pasithea Therapeutics (KTTA) Stock Down 12% Today?</a></li>
</ul>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771234">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771244">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/05/secret-income-blueprint-of-the-one-percent/?cid=MKT730394&amp;eid=MKT771242">The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2023/12/rblx-stock-alert-wells-fargo-initiates-roblox-coverage-with-overweight-rating/">RBLX Stock Alert: Wells Fargo Initiates Roblox Coverage With &#8216;Overweight&#8217; Rating</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

RBLX Stock Alert: Wells Fargo Initiates Roblox Coverage With 'Overweight' Rating

Pasithea conducts 1-for-20 reverse stock split, gets FDA okay for study

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth checking out on Friday as we get into all of the biggest news affecting shares on the final day of trading this week!



Moving stocks today are public offerings, an earnings report and more.



Let&rsquo;s dive into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Aclarion (NASDAQ:<a href="https://investorplace.com/stock-quotes/acon-stock-quote/">ACON</a>) stock is rocketing more than 79% alongside heavy pre-market trading.</li>



<li>Himalaya Shipping (NYSE:<a href="https://investorplace.com/stock-quotes/hshp-stock-quote/">HSHP</a>) shares are soaring over 21% without any clear news this morning.</li>



<li>Ekso Bionics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ekso-stock-quote/">EKSO</a>) stock is surging more than 20% with strong early morning trading.</li>



<li>Panbela Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/pbla-stock-quote/">PBLA</a>) shares are gaining over 19% as it prepares for a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318006293&amp;type=PDF&amp;symbol=PBLA&amp;cdn=255e23064a07775ab2cefc841a6dd3b1&amp;companyName=Panbela+Therapeutics+Inc.&amp;formType=S-1%2FA&amp;formDescription=%5BAmend%5D+General+form+for+registration+of+securities+under+the+Securities+Act+of+1933&amp;dateFiled=2024-01-25">proposed public offering</a>.</li>



<li>Ucommune International (NASDAQ:<a href="https://investorplace.com/stock-quotes/uk-stock-quote/">UK</a>) stock is increasing more than 18% on Friday morning.</li>



<li>The Real Brokerage (NASDAQ:<a href="https://investorplace.com/stock-quotes/reax-stock-quote/">REAX</a>) shares are rising over 18% after <a href="https://www.nasdaq.com/press-release/the-real-brokerage-invites-you-to-join-us-at-the-microcap-conference-2024-01-25">announcing a presentation next week</a>.</li>



<li>BIT Mining Limited (NYSE:<a href="https://investorplace.com/stock-quotes/btcm-stock-quote/">BTCM</a>) stock is climbing more than 16% on Friday.</li>



<li>Lixiang Education (NASDAQ:<a href="https://investorplace.com/stock-quotes/lxeh-stock-quote/">LXEH</a>) shares are getting an over 15% boost after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318005286&amp;type=PDF&amp;symbol=LXEH&amp;cdn=6639882602bf7fce8ca884d95ec782b1&amp;companyName=Lixiang+Education+Holding+Co.+Ltd.&amp;formType=6-K&amp;formDescription=Report+of+foreign+private+issuer+pursuant+to+Rule+13a-16+or+15d-16+under+the+Securities+Exchange+Act+of+1934&amp;dateFiled=2024-01-25">regaining Nasdaq compliance</a>.</li>



<li>Porch Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/prch-stock-quote/">PRCH</a>) stock is jumping more than 14% <a href="https://www.nasdaq.com/press-release/porch-group-receives-%2425m-with-signing-of-strategic-agreement-with-aon-2024-01-25">alongside a strategic agreement</a>.</li>



<li>Pasithea Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ktta-stock-quote/">KTTA</a>) shares are up over 14% today.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Aptose Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/apto-stock-quote/">APTO</a>) stock is plummeting more than 26% as <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318008758&amp;type=PDF&amp;symbol=APTO&amp;cdn=12b3da5a3896f2a507db32324ce6eb5a&amp;companyName=Aptose+Biosciences+Inc.&amp;formType=EFFECT&amp;formDescription=Notice+of+Effectiveness&amp;dateFiled=2024-01-25">a public offering goes into effect</a>.</li>



<li>SU Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUGP#NASDAQ">SUGP</a>) shares are diving over 21% following its recent <a href="https://www.nasdaq.com/press-release/su-group-holdings-limited-announces-pricing-of-initial-public-offering-2024-01-23">initial public offering (IPO)</a>.</li>



<li>Eve&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/evex-stock-quote/">EVEX</a>) stock is tumbling more than 19% despite a lack of news.</li>



<li>Paramount Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/para-stock-quote/">PARA</a>) shares are retreating over 18% after <a href="https://investorplace.com/2024/01/para-stock-alert-is-david-ellison-about-to-take-paramount-global-private/">rising yesterday on acquisition reports</a>.</li>



<li>LAVA Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/lvtx-stock-quote/">LVTX</a>) stock is taking a more than 12% beating <a href="https://www.marketwatch.com/story/lava-therapeutics-shares-rise-as-drug-set-for-test-with-merck-s-keytruda-c936d7cd">after rallying yesterday</a>.</li>



<li>Nxu (NASDAQ:<a href="https://investorplace.com/stock-quotes/nxu-stock-quote/">NXU</a>) shares are dropping over 12% after <a href="https://www.nasdaq.com/press-release/nxu-submits-for-nevi-grant-funding-to-enhance-its-major-highway-electrification-goals">seeking new grant funding</a>.</li>



<li>Sagimet Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/sgmt-stock-quote/">SGMT</a>) stock is decreasing more than 11% with <a href="https://finance.yahoo.com/news/sagimet-biosciences-announces-proposed-public-224500288.html">public offering plans</a>.</li>



<li>Integrated Media Technology (NASDAQ:<a href="https://investorplace.com/stock-quotes/imte-stock-quote/">IMTE</a>) shares are falling over 11% on Friday.</li>



<li>Intel (NASDAQ:<a href="https://investorplace.com/stock-quotes/intc-stock-quote/">INTC</a>) stock is sliding more than 10% with <a href="https://www.cnbc.com/2024/01/25/intel-intc-earnings-report-q4-2023.html">Q4 earnings results</a>.</li>



<li>Clearmind Medicine (NASDAQ:<a href="https://investorplace.com/stock-quotes/cmnd-stock-quote/">CMND</a>) shares close out our pre-market stock movers down over 10%.</li>
</ol>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/01/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-jan-26th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

AAMC

ACHV

ACON

APTO

AULT

BRSH

BTCM

CCCC

CCLD

CISO

CMND

CNTB

CREV

EDSA

EKSO

EVEX

GEHI

HCDI

HRYU

HSHP

ICVX

IMTE

INAB

INPX

INTC

IOAC

LFMD

LPTV

LVTX

LXEH

MYNA

NFTG

ONCT

PARA

PBLA

PLTR

PRCH

RBLX

REAX

RSLS

SFWL

SGMT

SNTI

STTK

SUGP

SVMH

SVMHW

VSME

Press Releases

Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS

Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development

Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders

Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models

Pasithea Therapeutics Announces Results from 2023 Annual Meeting

Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023

Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients

Health Care

Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position

Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004

Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers

KTTAW

Ainos